Correction: New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A/Nrp1 pathway

Affiliations

• ¹ National Institute of Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK. Sobha.sivaprasad@nhs.net.
• ² University College London Institute of Ophthalmology, London, UK. Sobha.sivaprasad@nhs.net.
• ³ SingHealth Research, Singapore, Singapore.
• ⁴ Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
• ⁵ Retina Consultants of Texas, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA.
• ⁶ Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
• ⁷ Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
• ⁸ Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.